Last reviewed · How we verify

NCT07055867

Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)

ENROLLING BY INVITATION Last updated 9 July 2025
What this trial tests

trial in Mpox (Monkeypox) in 122 participants. Enrolling by invitation.

Timeline
1 August 2024
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorOsaka Metropolitan University
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment122
Start date1 August 2024
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Democratic Republic of the Congo

Conditions studied

Sponsor

Osaka Metropolitan University

Who can join

Eligibility, any sex, with Mpox (Monkeypox). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to characterize the clinical features of the 2024 mpox outbreak in Equateur Province of DRC and to identify associated risk factors. The main question it aims to answer is: * What are the clinical features of the 2024 mpox outbreak in Equateur Province of DRC? * What are the associated risk factors of the 2024 mpox outbreak? Participants which has mpox like symptoms will answer mpox investigations related questions and be collected skin lesions and whole blood samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mpox (Monkeypox)

Currently open trials in the same condition.

Other Osaka Metropolitan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07055867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing